Hemophilia Market

SKU: DMPH2672 | Last Updated On: Nov 09 2022 | Available Formats

> Hemophilia Market Expected to reach at a high CAGR of 5.2% during the forecast period 2022-2029: DataM Intelligence

Hemophilia Market is segmented By Disease Type (Hemophilia A, Hemophilia B, Hemophilia C, Others), By Therapy (Replacement Therapy, Gene Therapy, ITI therapy), By Product Type (Recombinant Coagulation, Factor Concentrates, Plasma-derived Coagulation, Factor Concentrates, Others), and By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) – Share, Size, Outlook, and Opportunity Analysis, 2022-2029


Market Overview

[195 Pages Report] The Hemophilia Market size was valued at USD 13,261.90 million in 2021 and is estimated to reach at a compound annual growth rate (CAGR) of 5.2% over the forecast period from 2022 to 2029.

Hemophilia is an inherited bleeding disorder in which a person lacks or has low levels of certain proteins called “clotting factors” and the blood doesn’t clot properly as a result. This leads to excessive bleeding. There are 13 types of clotting factors, and these work with platelets to help the blood clot. People with hemophilia have low levels of either factor VIII (8) or factor IX (9). The amount of bleeding depends on the severity of hemophilia.

The global hemophilia market growth is driven by the rising need for hemophilia medicines to cater to the crucial medicinal requirement to limit blood loss is one of the prime growth factors for the global hemophilia market. Also, the unavailability of any firm cure that can eliminate the disorder from the body of patients is influencing the growth of the global hemophilia market.

Hemophilia Market Scope



Market CAGR


Segments Covered

By Disease Type, By Therapy, By Product Type, and By Region

Report Insights Covered

Competitive Landscape Analysis, Company Profile Analysis, Market Size, Share, Growth, Demand, Recent Developments, Mergers and acquisitions, New Product Launches, Growth Strategies, Revenue Analysis, and Other key insights.

Fastest Growing Region

Asia Pacific

Largest Market Share 

North America

For More Insights, Download Sample Brochure

Market Growth     

The rising grants for research on hemophilia are further expected to contribute to the market over the forecast period. For instance, in March 2022, with the support of USD 12 million funding from the National Heart, Lung, and Blood Institute, an Indiana University School of Medicine researcher will head a multi-institute effort to develop hemophilia medicines. This will lead to the development of novel therapies for hemophilia thereby expected to drive the market growth over the forecast period.

In addition, rising product approvals for the United States Food and Drug Administration are further expected to propel market growth. For instance, in April 2020, The United States Food and Drug Administration approved Sevenfact for the treatment and control of bleeding episodes occurring in adults and adolescents 12 years of age and older with hemophilia A or B with inhibitors (neutralizing antibodies).

Furthermore, according to the World World Federation of Hemophilia's October 2021 report, owing to the sex-linkage of the disorder, there is a bigger prominence in males than females. Hemophilia occurs worldwide and across all racial groups. According to the World Federation of Hemophilia global report published in October 2021, there were 209,614 people diagnosed with hemophilia including 165,379 Hemophilia A patients, 33,076 Hemophilia B patients, and 11,159 Hemophilia type unknown patients globally. These factors are driving the growth of the market in the forecast period.

The high cost of treatment of hemophilia will hamper the growth of the market

However, the high cost of treatment of hemophilia along with the lack of awareness among people regarding advanced technologies is expected to hinder the market studied.

COVID-19 Impact Analysis

The outbreak of COVID-19 worldwide is expected to impact the market, as individuals with chronic medical conditions, such as hemophilia, should take extra precautions to minimize the risk of contracting COVID-19, as this group of the population is more prone to infectious diseases.

In addition, according to the study published in the Journal of Dental and Medical Sciences, titled 'Impact of Covid-19 pandemic on Hemophilia prophylaxis in children: experience of a hemophilia treatment center in West Bengal, India' in August 2020, the mean annualized bleed rate before the lockdown was 2.4, whereas it significantly increased to 8.2 during the lockdown in children who were on regular prophylaxis earlier. Among various reasons cited by them for not attending a Hemophilia treatment center, the important reasons were non-availability of transport (97.5%), fear of coronavirus infection (95%), and high cost of alternate transport (90%). This has down the market growth during the pandemic.

Segment Analysis

The Hemophilia A segment is expected to grow at the fastest CAGR during the forecast period (2022-2029)        

Hemophilia A is expected to hold a significant market share over the forecast period. Hemophilia A is the most common severe bleeding disorder. Replacement therapy, providing the missing coagulation factor, has been the mainstay of treatment both prophylactically and to treat bleeding.

According to the data published by the World Federation of Hemophilia in 2021, in 2020, hemophilia A is more recorded among males accounting for 146,246 (88%), followed by females with 5,636 (3%) and sex not known 9,917 (6%). The key medication to treat hemophilia A has concentrated FVIII product, also known as a clotting factor. The recombinant factor products that are developed in a laboratory using DNA technology impede the use of human-derived pools of donor-sourced plasma due to the advances in recombinant protein engineering and the introduction of gene therapy and novel strategies to target the coagulation cascade. For instance, in December 2021, Pfizer Inc. and Sangamo Therapeutics, Inc., a genomic medicines company, released updated follow-up data from the Phase 1/2 Alta study of giroctocogene fitelparvovec, investigational gene therapy for patients with moderately severe to severe hemophilia A. The rise in research on gene therapies for Hemophilia A is therefore expected to drive the growth of this segment.

Geographical Analysis

North America region holds the largest market share of the global hemophilia market 

North America dominates the hemophilia market and is expected to show a similar trend over the forecast period, owing to the therapeutic advances in hemophilia, which led to a wave of new Food and Drug Administration-approved agents and increasing awareness about technologically advanced products, increasing prevalence of hemophilia, and the presence of a huge patient pool.

The United States is the largest market in the region. According to the World Federation of Hemophilia 2021 report, there were about 14,816 patients with hemophilia including (Hemophilia A -11,790 and Hemophilia B-3,026) in the United States in 2020 and people diagnosed with hemophilia in the United States and 3,924 patients with hemophilia in Canada in 2020 including (Hemophilia A -3,223 and Hemophilia B-701). Such a high number of hemophilia cases in these regions is expected to drive the growth of the market in this region due to the higher adoption of therapies for hemophilia.

In addition, according to the news in November 2021 in the United States, researchers of Spark Therapeutics suggest that gene therapy can reduce, and even stop, potentially life-threatening bleeding episodes in persons with hemophilia. The novel adeno-associated viral (AAV) vector-based gene therapy is intended to help hemophilia A sufferers express FVIII in their livers, and a phase 1/2 clinical study indicated that it did so in the majority of patients. The rise in research on gene therapies and favorable results of the same is thereby expected to drive the growth of this market in the United States over the forecast period.

Competitive Landscape

The hemophilia market is a moderately competitive presence of local as well as global companies.  Some of the key players which are contributing to the growth of the market include Bayer AG, BioMarin Pharmaceutical, Inc., CSL Behring, Kedrion S.p.A, Novo Nordisk, Pfizer, Inc., Roche (Chugai Pharmaceutical Co.), Sanofi (Genzyme Corporation), and Takeda Pharmaceutical (Shire Plc.), Grifols among others. The major players are adopting several growth strategies such as product launches, acquisitions, and collaborations, which are contributing to the growth of the hemophilia market globally. For instance, in March 2022, Freeline Therapeutics Holdings plc dosed the first patient in its Phase 1/2 B-LIEVE dose-confirmation clinical trial of FLT180a for the treatment of hemophilia B, a debilitating genetic bleeding disorder caused by a deficiency in the clotting factor IX protein.

Bayer AG


Bayer AG produces and markets healthcare and agricultural products. The Company manufactures products that include aspirin, antibiotics, anti-Infectives, cardiovascular, oncology, central nervous system drugs, over-the-counter medications, diagnostics, and animal health products, as well as crop protection products, plastics, and polyurethanes.     

Product Portfolio:

Jivi:  Jivi is an injectable medicine used to replace clotting factor (Factor VIII or ant hemophilic factor) that is missing in people with hemophilia A.  Jivi is not for use in children below 12 years of age or previously untreated patients.

Trending Topics

Lyme Disease Diagnostics Market

Fabry Disease Treatment Market

Remote Patient Monitoring Market

Did not find what you were looking for?Every 7 out of 10 customers request tailored reports. Get yours today!
We collate your requirements.
Our global research team is put into action.
We deliver, and make sure your endeavour is a success!

Buy This Report

20% Discount Applied*

Note*: For "Bundle/Bulk" Subscription of Reports,
please contact: [email protected]

Get your free sample proposal with a single click!